The latest news on many topics all here for you! Relax, enjoy, read.

Saturday, May 19, 2012 4:04 PM

For all sports news, visit sportingnewssite.info
go to deltaville, va pages

BioTech News Headlines - Yahoo! News
Gene Tests May Not Drive Patients to More Medical Care
5/18/2012 11:50:08 PM
FRIDAY, May 18 (HealthDay News) -- Personal genetic testing does not lead to an increased use of health services, a new study finds.
Osiris shares climb on stem-cell therapy approval
5/18/2012 10:50:16 AM
Shares of Osiris Therapeutics traded higher Friday, a day after Canadian regulators approved the company's first-of-a-kind stem cell therapy Prochymal, a treatment for a deadly side effect of bone marrow transplants.
Canada OKs Osiris drug; first stem cell therapy
5/17/2012 9:57:22 PM
BOSTON (Reuters) - Osiris Therapeutics Inc said on Thursday that Canadian health regulators have approved its treatment for acute graft-versus host disease in children, making it the first stem cell drug to be approved for a systemic disease anywhere in the world. Osiris shares rose 14 percent to $6.00 in extended trading after the news was announced. Graft versus host disease (GvHD) is a potentially deadly complication from a bone marrow transplant, when newly implanted cells attack the patient's body. ...
Canada OKs Osiris drug; first stem cell therapy
5/17/2012 7:08:55 PM
BOSTON (Reuters) - Osiris Therapeutics Inc said on Thursday that Canadian health regulators have approved its treatment for acute graft-versus host disease in children, making it the first stem cell drug to be approved for a systemic disease anywhere in the world. Osiris shares rose 14 percent to $6.00 in extended trading after the news was announced. Graft versus host disease (GvHD) is a potentially deadly complication from a bone marrow transplant, when newly implanted cells attack the patient's body. ...
Osiris stem cell therapy approved in Canada
5/17/2012 6:22:40 PM
Osiris Therapeutics Inc. said Thursday that Canadian regulators approved its stem cell therapy Prochymal, which is intended to treat a deadly side effect of bone marrow transplants.
Study unpicks gene changes behind breast cancer
5/17/2012 12:12:35 PM

A woman undergoes a free mammogram inside Peru's first mobile unit for breast cancer detection, in LimaLONDON (Reuters) - Scientists have mapped the complete genetic codes of 21 breast cancers and created a catalogue of the mutations that accumulate in breast cells, raising hopes that the disease may be able to be spotted earlier and treated more effectively in future. The research, the first of its kind, untangles the genetic history of how cancer evolves, allowing scientists to identify mutational patterns that fuel the growth of breast tumors, and start to work out the processes behind them. ...


B.C.'s organic growers browned off by bid to wipe browning gene from apples
5/17/2012 12:08:40 PM
KELOWNA, B.C. - Orchardists in B.C.'s Okanagan region worry that the introduction of genetically modified trees could take a bite out of fruit sales.
Genetic Test May Spot Raised Autism Risk
5/16/2012 11:52:06 PM
WEDNESDAY, May 16 (HealthDay News) -- Researchers report that a new DNA test may be able to spot an increased risk of autism in children as young as 6 months old.
Stem Cell Study Shows Promising Results Against Heart Failure
5/10/2012 11:52:09 PM
THURSDAY, May 10 (HealthDay News) -- A new treatment that involves spinning bone marrow stem cells to enhance their healing potential may help people with advanced heart failure feel and function better, a small study suggests.
Onetime "King of Biotech" runs afoul of law again
5/10/2012 9:50:37 AM
NEW YORK (Reuters) - David Blech, an investor who was known as the "King of Biotech" before he admitted to criminal charges of stock manipulation in 1998, has run into trouble with the law again over illegal trades in stocks of two biopharmaceutical companies. Blech told a federal judge in New York on Wednesday that in 2007 and 2008 he bought and sold stocks of Pluristem Therapeutics Inc and Intellect Neurosciences Inc in quick succession to try and conceal his own sales that might have reduced the stock's value. ...


Daily Read

Worth a visit